Latest News

19 September 2017

SpeeDx and Diagen sign new distribution agreement for Scandinavia

SpeeDx Pty, Ltd. has announced a distribution agreement with Diagen, a leading Scandinavian clinical laboratory supplier specialising in diagnostic products....

Read More

4 September 2017

SpeeDx Awarded A$2.5 million by NSW Medical Devices Fund

SpeeDx Pty. Ltd. are among the recipients of the New South Wales Medical Devices Fund (MDF) 2017-2018, announced last night....

Read More

9 June 2017

SpeeDx and Cepheid Announce European Distribution Partnership

Strategic commercial partnership in key European markets with Cepheid. SYDNEY, AUSTRALIA--(Marketwired - Jun 8, 2017) - SpeeDx Pty, Ltd., a developer...

Read More

26 April 2017

SpeeDx and Thermo Fisher Scientific Strategic Partnership

SpeeDx and Thermo Fisher Scientific Announce Strategic Partnership for FDA Clearance of Molecular Diagnostic. ResistancePlus™ MG Test would bring disease and...

Read More

6 April 2017

Prospective Evaluation Study for ResistancePlus^® MG

  A prospective evaluation study published in the Journal of Clinical Microbiology evaluated our ResistancePlus® MG assay against 1089 symptomatic and asymptomatic...

Read More

17 February 2017

Nature Reviews Urology | Growing threat of macrolide resistant M. genitalium infections.

The authors of the review, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium, published in Nature Review Urology recommended that...

Read More